enquiry@dsij.in |+91 9240904920
SENSEX-307.24
76,957.27-0.4%

Fine Organic Industries' SEZ and US capex set up multi-year volume scale-up

Fine Organic Industries Ltd.

Broker Recommendation:

BUY

Broker: Anand Rathi Research

11 Aug 2026

Sector: Chemicals

Reco. Price

₹5,121

CMP

₹5,265.3

Target

₹6,000

Upside

17.16%

Investment View

In its August 11, 2026 result update on Fine Organic Industries, Anand Rathi Research maintains its BUY rating. The broker views the company as positioned for a multi-year, capacity-led scale-up despite limited near-term volume growth.

The JNPA SEZ facility is expected to begin contributing from H2 FY28E, while the US plant is expected to contribute from FY29E. Fine Organic Industries has around Rs 14,000 crore of cash and is expected to generate around Rs 7,500 crore of cash over FY27E-FY28E. Anand Rathi believes this should enable the company to fund expansion and higher working-capital needs through internal accruals.

Q1 FY27 Financial Performance

Fine Organic Industries reported a stronger-than-expected Q1 FY27 performance. Consolidated revenue rose 18 per cent year on year and 11 per cent quarter on quarter to Rs 694 crore, exceeding Anand Rathi's estimate by 12.5 per cent and consensus by 11.3 per cent. Exports accounted for around 60 per cent of revenue.

Metric Q1 FY27 Year-on-year change Quarter-on-quarter change Comparison with Anand Rathi estimate
Consolidated revenue Rs 694 crore 18% increase 11% increase 12.5% above estimate
Gross margin 45.4% Up 496 bps Up 508 bps
EBITDA Rs 176 crore 42% increase 36% increase 37.7% above estimate
EBITDA margin 25.3%
Adjusted profit after tax Rs 138 crore 23% increase 18% increase 28% above estimate
Other income Rs 24 crore 39% decline

Gross margin expanded to 45.4 per cent, reflecting contractual pricing resets and the pass-through of higher raw-material, utility and freight costs. EBITDA margin rose to 25.3 per cent. Other income declined 39 per cent year on year to Rs 24 crore.

Capacity Expansion and Execution

Management indicated that all plants are operating at optimal utilisation except Patalganga, where some volume headroom remains until the new capacity starts.

  • The JNPA SEZ plant is expected to commence operations in H2 FY28, around 30 months after environmental clearance.
  • Construction contractor hiring for the SEZ project slipped through most of Q1 FY27. Construction work in progress stood at Rs 60 crore on June 30, 2026, below Anand Rathi's estimate.
  • Fine Organic Industries is in advanced discussions with contractors for US Phase I.
  • Management expects the US facility to be ready 18 to 24 months after construction begins and plans to scale up gradually to reduce risk in the new market.

Earnings Outlook and Estimates

Anand Rathi expects higher vegetable-oil prices to support realisations through FY27E. The raw-material basket rose 5 to 15 per cent quarter on quarter because of biodiesel demand and higher crude prices. The broker notes that demand has low sensitivity to price, supporting earnings even as volume growth remains soft.

Anand Rathi raised its FY27E revenue, EBITDA, adjusted profit after tax and EPS estimates by 2.9 per cent, taking FY27E EPS to Rs 153.7. FY28E estimates are broadly unchanged, with EPS at Rs 171.4.

Financial year Revenue EBITDA EPS
FY27E Rs 2,691 crore Rs 569 crore Rs 153.7
FY28E Rs 3,164 crore Rs 696 crore Rs 171.4

Valuation and Target Price

Anand Rathi's target price of Rs 6,000 is based on 35 times FY28E EPS and incorporates the delay in capacity monetisation. At the report's CMP of Rs 5,121, Fine Organic Industries traded at 33 times FY27E EPS and 30 times FY28E EPS.

The broker considers the valuation attractive in light of the company's execution record of more than 20 per cent earnings CAGR and around 34 per cent average return on capital employed over the past decade. Current return on invested capital is around 33 per cent.

Key Risks

  • Delays in capex execution.
  • Volatility in input prices.
View / Download Original Research Report

Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.